We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App




C-Reactive Protein Predicts Neurological Outcomes of Subarachnoid Hemorrhage Patients

By LabMedica International staff writers
Posted on 07 Apr 2020
Print article
Image: Early serial measurements of C-reactive protein predicts the outcome in patients with subarachnoid hemorrhage (Photo courtesy of Blue Horizon).
Image: Early serial measurements of C-reactive protein predicts the outcome in patients with subarachnoid hemorrhage (Photo courtesy of Blue Horizon).
Subarachnoid hemorrhage (SAH) is a disease associated with high mortality. Survivors of SAH may manifest severe neurological deficits. In patients with SAH, early brain injury or delayed cerebral ischemia (DCI) is associated with poor outcomes.

C-reactive protein (CRP) is a useful marker of non-specific inflammation. Elevated CRP levels might be associated with the progression of vascular disease. Elevated levels of CRP are significantly associated with unfavorable long-term functional outcome in patients with ischemic stroke. The measurement of CRP significantly increases the ability to make accurate predictions and prevent or manage coronary thrombotic events appropriately.

Neurologists at the Samsung Medical Center (Seoul, Republic of Korea) carried out a retrospective, single-center, observational study of adult patients with SAH who were admitted to the neurosurgical intensive care unit (ICU) from January 2012 through June 2017. A total of 156 patients diagnosed with SAH were analyzed in the study. Initial brain CT and CT angiography were performed within 12 hours from the onset of SAH.

Initial CRP levels were measured within 12 hours after admission. The day of admission was defined as day 1. CRP data on days 1 to 7 were collected. Serum CRP levels were measured using the CRPL3 immunoturbidimetric assays (Roche Diagnostics, Indianapolis, IN, USA) with a lower reference limit of 0.3 mg/dL. The maximal level of CRP (CRPMax) was defined as the peak level from days 1 through 4. Subsequent CRP (CRPmin) level was determined as the minimal level from days 5 to 7.

The scientists reported that among 156 patients with SAH, 145 (92.9%) survived until discharge. Of these survivors, 109 (69.9%) manifested favorable neurological outcomes. Initial CRP levels on admission and maximal CRP levels within four days were significantly higher in the group with poor neurological outcome compared with those manifesting favorable neurological outcomes. Prediction of poor neurological outcome showed that the performance of the maximal CRP was significantly better compared with the initial CRP or the clearance of CRP. The maximal CRP levels within four days facilitate the prediction of neurological outcomes of SAH patients without surgical clipping.

The authors concluded that early serial measurements of CRP may be used to predict neurological outcomes of SAH patients. Furthermore, maximal CRP levels within four days post-SAH are significantly correlated with poor neurological outcomes. The study was published on march 27, 2020 in the journal BMC Neurology.

Related Links:
Samsung Medical Center
Roche Diagnostics


Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Troponin I Test
Quidel Triage Troponin I Test
New
Centrifuge
Hematocrit Centrifuge 7511M4

Print article

Channels

Molecular Diagnostics

view channel
Image: Researcher Kanta Horie places a sample in a mass spectrometer that measures protein levels in blood plasma and other fluids (Photo courtesy of WashU Medicine)

Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression

Several blood tests are currently available to assist doctors in diagnosing Alzheimer's disease in individuals experiencing cognitive symptoms. However, these tests do not provide insights into the clinical... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.